drugset / Trial / NCT00595686

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

NCT00595686

Phase 1 Completed 25 enrolled Esanex Inc. Serenex, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Timeline

Start
2008-01
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SNX-5422 Small molecule Oral